Spotlight on Radiology

Kevin R. Flaherty, MD, MS
Credits: 0.25 CME
Clinical Presentation and Identification of CF-ILD: Journey to a Diagnosis of IPF
Kevin R. Flaherty, MD, MS
Vindico Medical Education

Clinical Presentation and Identification of CF-ILD: Journey to a Diagnosis of IPF

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
  • Evaluate optimal treatment strategies for patients with CF-ILD.

Activity Description

In this educational video, Drs. Kevin Flaherty and Marilyn Glassberg discuss the workup and clinical course of a patient with idiopathic pulmonary fibrosis.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Marilyn Glassberg, MD
Scientific Advisory Committee
Division Chief, Pulmonary Medicine, Critical Care and Sleep Medicine
University of Arizona College of Medicine
Phoenix, AZ

Relevant Disclosures:
Advisor: Bellerophon Therapeutics
Consultant: Genentech/Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
  • Evaluate optimal treatment strategies for patients with CF-ILD.

Activity Description

In this educational video, Drs. Kevin Flaherty and Marilyn Glassberg discuss the workup and clinical course of a patient with idiopathic pulmonary fibrosis.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Marilyn Glassberg, MD
Scientific Advisory Committee
Division Chief, Pulmonary Medicine, Critical Care and Sleep Medicine
University of Arizona College of Medicine
Phoenix, AZ

Relevant Disclosures:
Advisor: Bellerophon Therapeutics
Consultant: Genentech/Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Radiology Presentations

Kevin R. Flaherty, MD, MS
0.25 CME
Vindico Medical Education
Clinical Presentation and Identification of CF-ILD: Journey to a Diagnosis of IPF

Clinical Presentation and Identification of CF-ILD: Journey to a Diagnosis of IPF

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
  • Evaluate optimal treatment strategies for patients with CF-ILD.

Activity Description

In this educational video, Drs. Kevin Flaherty and Marilyn Glassberg discuss the workup and clinical course of a patient with idiopathic pulmonary fibrosis.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Marilyn Glassberg, MD
Scientific Advisory Committee
Division Chief, Pulmonary Medicine, Critical Care and Sleep Medicine
University of Arizona College of Medicine
Phoenix, AZ

Relevant Disclosures:
Advisor: Bellerophon Therapeutics
Consultant: Genentech/Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
  • Evaluate optimal treatment strategies for patients with CF-ILD.

Activity Description

In this educational video, Drs. Kevin Flaherty and Marilyn Glassberg discuss the workup and clinical course of a patient with idiopathic pulmonary fibrosis.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Marilyn Glassberg, MD
Scientific Advisory Committee
Division Chief, Pulmonary Medicine, Critical Care and Sleep Medicine
University of Arizona College of Medicine
Phoenix, AZ

Relevant Disclosures:
Advisor: Bellerophon Therapeutics
Consultant: Genentech/Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Lisa H. Lancaster, MD
0.25 CME
Vindico Medical Education
Choosing the Optimal Treatment in a Patient With Progressive Fibrosing ILD

Choosing the Optimal Treatment in a Patient With Progressive Fibrosing ILD

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
  • Evaluate optimal treatment strategies for patients with CF-ILD.
  • Review up-to-date clinical data for the management of patients with CF-ILD in the era of COVID-19.

Activity Description

In this educational video, Drs. Kevin Flaherty and Lisa Lancaster discuss the assessment and management of a patient with chronic hypersensitivity pneumonitis.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Lisa H. Lancaster, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Relevant Disclosures:
Advisor: Bellerophon, United Therapeutics
Consultant: Bellerophon, Genentech, United Therapeutics
Speaker Contracted by Ineligible Company: Boehringer Ingelheim, Genentech
Independent Research Contractor (paid to institution): Boehringer Ingelheim, Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
  • Evaluate optimal treatment strategies for patients with CF-ILD.
  • Review up-to-date clinical data for the management of patients with CF-ILD in the era of COVID-19.

Activity Description

In this educational video, Drs. Kevin Flaherty and Lisa Lancaster discuss the assessment and management of a patient with chronic hypersensitivity pneumonitis.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Lisa H. Lancaster, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Relevant Disclosures:
Advisor: Bellerophon, United Therapeutics
Consultant: Bellerophon, Genentech, United Therapeutics
Speaker Contracted by Ineligible Company: Boehringer Ingelheim, Genentech
Independent Research Contractor (paid to institution): Boehringer Ingelheim, Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Lisa H. Lancaster, MD
0.25 CME
Vindico Medical Education
Managing Rheumatoid Arthritis-Associated ILD

Managing Rheumatoid Arthritis-Associated ILD

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Evaluate optimal treatment strategies for patients with CF-ILD.
  • Review up-to-date clinical data for the management of patients with CF-ILD in the era of COVID-19.
  • Examine the rationale for monitoring lung involvement in patients with diseases associated with CF-ILD.

Activity Description

In this educational video, Drs. Lisa Lancaster and Kevin Flaherty review the case of a patient with rheumatoid arthritis-associated interstitial lung disease.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Lisa H. Lancaster, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Relevant Disclosures:
Advisor: Bellerophon, United Therapeutics
Consultant: Bellerophon, Genentech, United Therapeutics
Speaker Contracted by Ineligible Company: Boehringer Ingelheim, Genentech
Independent Research Contractor (paid to institution): Boehringer Ingelheim, Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.

Learning Objectives

Upon successful completion of these activities, participants should be better able to:

  • Evaluate optimal treatment strategies for patients with CF-ILD.
  • Review up-to-date clinical data for the management of patients with CF-ILD in the era of COVID-19.
  • Examine the rationale for monitoring lung involvement in patients with diseases associated with CF-ILD.

Activity Description

In this educational video, Drs. Lisa Lancaster and Kevin Flaherty review the case of a patient with rheumatoid arthritis-associated interstitial lung disease.

Activity Chair

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim

Faculty

Lisa H. Lancaster, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Relevant Disclosures:
Advisor: Bellerophon, United Therapeutics
Consultant: Bellerophon, Genentech, United Therapeutics
Speaker Contracted by Ineligible Company: Boehringer Ingelheim, Genentech
Independent Research Contractor (paid to institution): Boehringer Ingelheim, Roche

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com